CG Oncology, Inc.
CGON$1.70B
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaDALLAS113 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
4
Next Catalyst
This month
Market Overview
Stock performance and key metrics
CGON News
Catalyst Timeline
4 upcoming, 0 past
Phase 3Next
Cretostimogene Grenadenorepvec Phase 3 Est. Readout
June 2026~EstimatedCretostimogene Grenadenorepvec367
Primary completion for Cretostimogene Grenadenorepvec trial (NCT06111235) in Non Muscle Invasive Bladder Cancer
SourcePhase 2
Ivaltinostat Phase 2 Est. Readout
June 2026~EstimatedIvaltinostat70
Primary completion for Ivaltinostat trial (NCT05249101) in Metastatic Pancreatic Adenocarcinoma
Source2 more catalysts beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Drug Pipeline
Cretostimogene Grenadenorepvec
High-Risk Non-Muscle-Invasive Bladder Cancer
CG0070
Non Muscle Invasive Bladder Cancer
Ivaltinostat
Metastatic Pancreatic Adenocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cretostimogene Grenadenorepvec | Phase 3 | High-Risk Non-Muscle-Invasive Bladder Cancer | - | - |
CG0070 | Phase 2 | Non Muscle Invasive Bladder Cancer | - | - |
Ivaltinostat | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply